New Beauty Research Initiative(NBRI) Announces Skin Epigenetics Study Findings

May 21, 2024 03:00 PM CEST | By Cision
 New Beauty Research Initiative(NBRI) Announces Skin Epigenetics Study Findings
Image source: Kalkine Media

SEOUL, South Korea, May 21, 2024 /PRNewswire/ -- The results of the skin epigenetics research conducted by New Beauty Research Initiative (NBRI), operated by Amorepacific in collaboration with the Department of Dermatology at Johns Hopkins University School of Medicine, were presented at the 81st SID Annual Meeting held in Dallas, Texas, from May 15 to 17, 2024, entitled "Evaluation of epigenetic changes related to skin aging."

This presentation encompassed research conducted by the Johns Hopkins team, involving the investigation of epigenetic changes across 67,000 gene blocks associated with endogenous and photodamage-induced aging, out of approximately 2.3 million gene blocks. Epigenetics is the study of how, even with identical genes, the phenotype can change and be inherited based on various environmental factors and lifestyle habits. A classic example is that identical twins, who share the same genetic makeup, can develop different health and skin conditions as they age, due to different living environments such as UV exposure, hazardous surroundings, smoking, and stress.

Amorepacific's unique compounds, BioGF1K (Ginsenomics) and RE.D Flavonoid (Camellia extract) were used to research the epigenetic control of skin aging. When treated to skin cells isolated from the skin of patients aged 65 and 70 years with progressed photoaging, an epigenetic improvement effect was observed in approximately 60% of the 67,000 gene blocks. This finding holds significant importance as it confirms the anti-aging efficacy of Amorepacific's ingredients on the skin.

Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center, stated, "This research result provides a valuable opportunity to significantly enhance the recognition of ginseng, a core ingredient of Sulwhasoo, through the collaborative research conducted with the Johns Hopkins Medicine Department of Dermatology, a leading global research institute." He further added, "Amorepacific will continue introducing products that incorporate NBRI research results and strive to ensure that customers around the world can experience the efficacy of our ginseng, camellia, and green tea ingredients at the forefront of New Beauty."

The Society for Investigative Dermatology (SID) has held annual meetings since its establishment in 1937. The 81st meeting in 2024 brought together over 1,600 prominent researchers, clinicians, and dermatology residents to discuss skin-related systemic diseases. This year's meeting featured the presentation of more than 1,000 new scientific findings.

In December 2022, Amorepacific launched the New Beauty Research Initiative, a collaborative research program with the Johns Hopkins University School of Medicine in the US. NBRI continues to undertake research partnerships in a variety of disciplines related to skin aging research.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles